yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q33767994-F2219B65-E76F-458D-947E-142C284109A4
Q33767994-F2219B65-E76F-458D-947E-142C284109A4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33767994-F2219B65-E76F-458D-947E-142C284109A4
Safety and tolerability of regadenoson CMR.
P2860
Q33767994-F2219B65-E76F-458D-947E-142C284109A4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33767994-F2219B65-E76F-458D-947E-142C284109A4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5d3db71fa242c5740d322fa4b576d9814fe7b2f3
P2860
Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.